Final data released overnight show Pfizer’s coronavirus disease 2019 (COVID-19) vaccine is 95% effective; the first at-home COVID-19 test receives a regulatory go-ahead; Amazon launches its first digital drugstore.
Citing that the coronavirus disease 2019 (COVID-19) vaccine it developed with BioNTech is as effective as those for shingles and measles, reports The Wall Street Journal, Pfizer announced overnight that it will seek FDA approval for the vaccine within days. Distribution could then occur by year-end for the vaccine, which final data show is 95% effective among those who developed at least 1 symptom of COVID-19, based on results from the nearly 44,000-person trial. Fatigue and headaches were 2 severe adverse effects reported by the participants, but no serious safety issues were seen, and the vaccine appears well tolerated.
A 30-minute, at-home, rapid test for COVID-19 has received the go-ahead from the FDA, notes The New York Times. Developed by Lucira Health in California, the nasal-swab test, which would cost close to $50 and require a prescription, is the first of several rapid tests approved by the FDA that can be performed entirely at home or a doctor’s office. Doing so eliminates the need to ship samples for analyzing and long wait times for results, by utilizing a battery-powered test cartridge that will light up as “positive” or “negative.” Any patient younger than 14 years will need an adult to run the test.
Based in the United States, Amazon Pharmacy’s new service offerings include accepting most major insurance plans, 40% discounts on brand name drugs, and free 2-day delivery for Prime members, according to CNN Business. There will also be savings benefits for uninsured individuals and those not wanting to invoke their insurance coverage. PillPack, another digital drugstore, was acquired by Amazon back in 2018, and Amazon Pharmacy is an extension of that. Discounts of up to 80% on generic medications will also be offered.
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More